Study of Orfadin® (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1)

Trial Profile

Study of Orfadin® (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Nitisinone (Primary)
  • Indications Tyrosinaemia type I
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2016 New trial record
    • 15 Jun 2016 According to Swedish Orphan Biovitrum media release, the company announced that the Food and Drug Administration (FDA) has approved a higher strength 20 mg capsule of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top